Organisation paid for research Program year 2025 Source: CMS Open Payments

Floridian Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$6,608,464

1,598 payments

Through program year 2025, Floridian Clinical Research is reported as receiving $6,608,464 in research payments, across 1,598 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $114,926 174
2024 Research $2,309 2
2023 Research $188,575 348
2022 Research $3,757,534 1,011
2021 Research $2,507,008 27
2020 Research $38,112 36

Breakdown

Who paid Research payments · program years 2020–2025
  1. AstraZeneca UK Limited $5,347,119 5 payments
  2. AstraZeneca Pharmaceuticals LP $510,095 3 payments
  3. Regeneron Pharmaceuticals, Inc. $392,168 1,310 payments
  4. Boehringer Ingelheim International GmbH $210,155 179 payments
  5. Novo Nordisk AS $59,729 90 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $38,090 4 payments
  7. E.R. Squibb & Sons, L.L.C. $35,781 3 payments
  8. Boehringer Ingelheim RCV GmbH & Co KG $8,325 3 payments
  9. Incyte Corporation $7,000 1 payment
Studies the money was for Research payments · program years 2020–2025
  1. AZD2693, Cardiovascular, Renal and Metabolism $5,309,268 3 payments
  2. A Phase 2a Randomized Double blind Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease $486,608 3 payments
  3. Cross-Sectional Study to Determine Distribution of Genetic Variants Among Subjects at Risk of, or With Known Non-alcoholic Steatohepatitis (NASH) $392,168 1,310 payments
  4. MRD PoCP study in NFLD 12 wks $92,193 2 payments
  5. A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis $87,503 134 payments
  6. Nn9535-4321 $59,729 90 payments
  7. A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacodynamic Effects of MEDI0382 in Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH) $43,707 1 payment
  8. A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease $35,781 3 payments
  9. Phase IIa 8w $30,631 5 payments
  10. A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis $27,423 40 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record